SEC Comment Letter 0000000000-24-002905 to Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: March 15, 2024 · CIK: 0001595097 · Accession: 0000000000-24-002905
AI Filing Summary & Sentiment
File numbers found in text: 333-277888
Letter
United States securities and exchange commission logo March 15, 2024 Yuval Cohen, Ph.D. Chief Executive Officer Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 Re:Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed March 13, 2024 File No. 333-277888 Dear Yuval Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Lerner, Esq.
Show Raw Text
United States securities and exchange commission logo
March 15, 2024
Yuval Cohen, Ph.D.
Chief Executive Officer
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
Re:Corbus Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-3
Filed March 13, 2024
File No. 333-277888
Dear Yuval Cohen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael J. Lerner, Esq.